For Healthcare Professionals
Articles and Resources for ROS1+ Patients, Families, and Health Professionals.
Why Did My TKI Stop Working? Targeted Therapy and Acquired Resistance
What is Entrectinib (Rozlytrek)? How it Works, Side Effects and More
What is Targeted Therapy?
Confused about 1st and 2nd line drugs? Here’s a guide!
The ROS1ders Interview Dr. Ross Camidge
pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC
ROS1 News From Europe
Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors
Thinking about a “drug vacation” from crizotinib? Read this first!
Crizotinib approved for ROS1 in Australia
NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC
U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
Crizotinib may be effective again after chemo
TP Therapeutics Announces Interim Data from the Phase 1/2 Clinical Trial of Investigational Agent TP
Patients’ Tips on How to Deal with Common Side Effects of Crizotinib (aka Xalkori)